Skip to main content
TipRanks
Go Ultimate75% OFF

Daewon Pharmaceutical Co., Ltd (003220) Stock Statistics & Valuation Metrics

Total Valuation

Daewon Pharmaceutical Co., Ltd has a market cap or net worth of KRW 170.50B. The enterprise value is KRW 307.72B.

Market Cap
KRW 170.50B
Enterprise Value
KRW 307.72B

Share Statistics

Daewon Pharmaceutical Co., Ltd has 22,427,584 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
22,427,584
Owned by Insiders
―
Owned by Institutions
10.35%

Financial Efficiency

Daewon Pharmaceutical Co., Ltd’s return on equity (ROE) is -0.01 and return on invested capital (ROIC) is -0.49%.

Return on Equity (ROE)
-0.01
Return on Assets (ROA)
-0.00
Return on Invested Capital (ROIC)
-0.49%
Return on Capital Employed (ROCE)
0.01
Revenue Per Employee
448.95M
Profits Per Employee
-1.02M
Employee Count
1,349
Asset Turnover
0.99
Inventory Turnover
3.47

Valuation Ratios

The current PE Ratio of Daewon Pharmaceutical Co., Ltd is 12.68. Daewon Pharmaceutical Co., Ltd’s PEG ratio is -0.00.

PE Ratio
12.68
PS Ratio
0.27
PB Ratio
0.64
Price to FCF
-52.88
Price to Operating Cash Flow
8.83
PEG Ratio
-0.00

Income Statement

In the last 12 months, Daewon Pharmaceutical Co., Ltd had revenue of 605.64B and earned -1.38B in profits. Earnings per share was -64.37.

Revenue
605.64B
Gross Profit
266.09B
Operating Income
3.48B
Pretax Income
2.75B
Net Income
-1.38B
EBITDA
27.23B
Earnings Per Share (EPS)
-64.37

Cash Flow

In the last 12 months, operating cash flow was 18.97B and capital expenditures -22.14B, giving a free cash flow of -3.17B billion.

Operating Cash Flow
18.97B
Free Cash Flow
-3.17B
Free Cash Flow per Share
-147.90

Dividends & Yields

Daewon Pharmaceutical Co., Ltd pays an annual dividend of ―, resulting in a dividend yield of 3.20%

Dividend Per Share
―
Dividend Yield
3.20%
Payout Ratio
N/A
Free Cash Flow Yield
-1.89%
Earnings Yield
7.89%

Stock Price Statistics

Beta
0.03
52-Week Price Change
-39.85%
50-Day Moving Average
7913.80
200-Day Moving Average
9036.85
Relative Strength Index (RSI)
47.55
Average Volume (3m)
110.50K

Important Dates

Daewon Pharmaceutical Co., Ltd upcoming earnings date is Mar 12, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 13, 2026
Next Earnings Date
Mar 12, 2027
Ex-Dividend Date
―

Financial Position

Daewon Pharmaceutical Co., Ltd as a current ratio of 1.19, with Debt / Equity ratio of 70.35%

Current Ratio
1.19
Quick Ratio
0.73
Debt to Market Cap
0.71
Net Debt to EBITDA
5.14
Interest Coverage Ratio
0.48

Taxes

In the past 12 months, Daewon Pharmaceutical Co., Ltd has paid 4.75B in taxes.

Income Tax
4.75B
Effective Tax Rate
1.73

Enterprise Valuation

Daewon Pharmaceutical Co., Ltd EV to EBITDA ratio is -9.76, with an EV/FCF ratio of -103.94.

EV to Sales
0.54
EV to EBITDA
-9.76
EV to Free Cash Flow
-103.94
EV to Operating Cash Flow
17.37

Balance Sheet

Daewon Pharmaceutical Co., Ltd has KRW 51.11B in cash and marketable securities with KRW 186.37B in debt, giving a net cash position of -KRW 135.27B billion.

Cash & Marketable Securities
KRW 51.11B
Total Debt
KRW 186.37B
Net Cash
-KRW 135.27B
Net Cash Per Share
-KRW 6,031.24
Tangible Book Value Per Share
KRW 9,435.80

Margins

Gross margin is 45.26%, with operating margin of 1.07%, and net profit margin of 2.17%.

Gross Margin
45.26%
Operating Margin
1.07%
Pretax Margin
2.00%
Net Profit Margin
2.17%
EBITDA Margin
-5.53%
EBIT Margin
-9.71%

Analyst Forecast

The average price target for Daewon Pharmaceutical Co., Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
3.27%
EPS Growth Forecast
―

Scores

Smart Score
―
AI Score
51